Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007

Chest

Volumn 140, Issue 5, 2011, Pages 1261-1266

  Swigris, Jeffrey J ^a   Olson, Amy L ^a   Huie, Tristan J ^a   Fernandez Perez, Evans R ^a   Solomon, Joshua J ^a   Sprunger, David ^a   Brown, Kevin K ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DEATH; DEATH CERTIFICATE; DISEASE ASSOCIATION; FEMALE; HIGH RISK POPULATION; HUMAN; LUNG EMBOLISM; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; UNITED STATES;

EID: 81055141257     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0324     Document Type: Article

References (28)

1. Boeck C. Multiple benign sarcoid of the skin. J Cutan Genitourin Dis. 1899;17:543-550.
2. Baughman RP, Teirstein AS, Judson MA, et al.; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 pt 1):1885-1889. (Pubitemid 33152325)
3. Pietinalho A, Hiraga Y, Hosoda Y, Löfroos AB, Yamaguchi M, Selroos O. The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis. 1995;12(1):61-67.
4. Cozier YC, Berman JS, Palmer JR, Boggs DA, Serlin DM, Rosenberg L. Sarcoidosis in black women in the United States: data from the Black Women's Health Study. Chest.2011;139(1):144-150.
5. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153-2165.
6. Rybicki BA, Maliarik MJ, Major M, Popovich J Jr, Iannuzzi MC. Epidemiology, demographics, and genetics of sarcoidosis. Semin Respir Infect. 1998;13(3):166-173. (Pubitemid 28440835)
7. Chappell AG, Cheung WY, Hutchings HA. Sarcoidosis: a long-term follow up study. Sarcoidosis Vasc Diffuse Lung Dis.2000;17(2):167-173.
8. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 1983;52(208):525-533. (Pubitemid 14245588)
9. Hillerdal G, Nöu E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984;130(1):29-32. (Pubitemid 14092975)
10. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119(2):167-172.
11. Takada K, Ina Y, Noda M, Sato T, Yamamoto M, Morishita M. The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. J Clin Epidemiol. 1993;46(4):359-366. (Pubitemid 23149053)
12. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med.1991;151(5):933-938.
13. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975;17(4):259-270.
14. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 suppl 1):I4-I8. (Pubitemid 41289265)
15. Crawshaw AP, Wotton CJ, Yeates DG, Goldacre MJ, Ho LP. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax.2011;66(5):447.
16. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 2007;176(3):277-284. (Pubitemid 47195878)
17. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis- Interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183(3):372-378.
18. Hasday JD, Bachwich PR, Lynch JP III, Sitrin RG. Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis. Exp Lung Res.1988;14(2):261-278.
19. Kobayashi H, Gabazza EC, Taguchi O, et al. Protein C anticoagulant system in patients with interstitial lung disease. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1850-1854.
20. Nakstad B, Lyberg T, Skjønsberg OH, Boye NP. Local activation of the coagulation and fibrinolysis systems in lung disease. Thromb Res. 1990;57(6):827-838. (Pubitemid 20148998)
21. Chapman HA, Allen CL, Stone OL. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis. 1986;133(3):437-443. (Pubitemid 16126278)
22. Perez RL, Duncan A, Hunter RL, Staton GW Jr. Elevated D-dimer in the lungs and blood of patients with sarcoidosis. Chest. 1993;103(4):1100-1106. (Pubitemid 23110279)
23. Shorr AF, Hnatiuk OW. Circulating D-dimer in patients with sarcoidosis. Chest. 2000;117(4):1012-1016.
24. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375(9715):657-663.
25. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53(4):542-548. (Pubitemid 38372979)
26. Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology. 2010;139(3):779-787.
27. Newman LS, Rose CS, Bresnitz EA, et al. ACCESS Research Group. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324-1330. (Pubitemid 39657197)
28. Valeyre D, Soler P, Clerici C, et al. Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax. 1988;43(7):516-524.